Vertex (VRTX) legal chief sells 828 shares in pre-set 10b5-1 trade

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. As EVP and Chief Legal Officer, she sold 828 shares of Common Stock at a price of $439.91 per share on June 1, 2026. After this transaction, she directly holds 19,959 shares of Vertex common stock. The sale was made under a pre-arranged company-approved trading plan established pursuant to Rule 10b5-1, indicating it was scheduled in advance rather than timed discretionarily.

Insights

Equity compensation and insider-trading analyst

Pre-planned, modest open-market sale by a Vertex executive, with sizable holdings retained.

The filing shows EVP and Chief Legal Officer Joy Liu executed an open-market sale of 828 shares of Vertex Pharmaceuticals Common Stock at $439.91 per share. Following the trade, she continues to hold 19,959 shares directly, indicating only a small portion of her reported position was sold.

A key detail is the footnote stating the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 25, 2025. Such plans are established in advance and automatically trigger trades, so the timing typically reflects pre-scheduled portfolio management rather than a real-time view on the stock.

From an investor perspective, this looks like a routine, pre-planned disposition by a senior legal officer, not a large or surprising change in ownership. Future company filings will provide additional context if her trading pattern or share balance changes materially over time.

Insider Trade Summary 10b5-1

Net Seller: 828 shares ($364,245)

Net Sell 1 txn

Insider Liu Joy

Role EVP and Chief Legal Officer

Sold 828 shs ($364K)

Type	Security	Shares	Price	Value
Sale	Common Stock	828	$439.91	$364K

Holdings After Transaction: Common Stock — 19,959 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 828 shares Sale price per share: $439.91 per share Shares owned after sale: 19,959 shares +3 more

6 metrics

Shares sold 828 shares Open-market sale of Common Stock on June 1, 2026

Sale price per share $439.91 per share Price for the 828-share open-market sale

Shares owned after sale 19,959 shares Direct holdings following the reported transaction

Transaction date June 1, 2026 Date of the open-market sale

Trading plan adoption date November 25, 2025 Date Ms. Liu entered the Rule 10b5-1 plan

Net buy/sell shares −828 shares Net effect of reported transactions in this Form 4

Key Terms

Rule 10b5-1, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 regulatory

"company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Joy

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		828	D	$439.91	19,959	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Joy Liu report at Vertex (VRTX)?

Joy Liu reported an open-market sale of 828 shares of Vertex Common Stock. The shares were sold at a price of $439.91 per share on June 1, 2026. This was a standard non-derivative transaction in the company’s common equity.

How many Vertex (VRTX) shares does Joy Liu hold after this Form 4?

After the reported sale, Joy Liu directly holds 19,959 shares of Vertex Common Stock. This figure reflects her remaining position following the 828-share open-market sale disclosed in the Form 4, giving a sense of her ongoing equity stake in the company.

Was Joy Liu’s Vertex (VRTX) stock sale part of a Rule 10b5-1 plan?

Yes. A footnote states the transaction was made under a company-approved trading plan pursuant to Rule 10b5-1. The plan was entered into on November 25, 2025, indicating the sale was pre-scheduled rather than a spur-of-the-moment trading decision.

What price did Joy Liu receive for her sold Vertex (VRTX) shares?

The 828 Vertex shares were sold at an average price of $439.91 per share. This per-share price comes directly from the Form 4 transaction details and is used to quantify the value of the open-market sale executed on June 1, 2026.

What role does Joy Liu hold at Vertex (VRTX) in this Form 4 filing?

In this Form 4, Joy Liu is identified as an officer of Vertex, serving as EVP and Chief Legal Officer. Her position makes this a senior executive transaction, though the sale size is modest relative to her remaining 19,959-share direct holding.

Does the Form 4 for Vertex (VRTX) show any option exercises by Joy Liu?

No option exercises are shown in this data excerpt. The transaction involves only a non-derivative sale of Common Stock, and the derivativeSummary section is empty, indicating no derivative securities trades were reported in this particular filing.